Ahrén Bo
Department of Clinical Sciences, Division of Medicine, Lund University, SE-221 84 LUND, Sweden.
Curr Diab Rep. 2007 Oct;7(5):340-7. doi: 10.1007/s11892-007-0056-9.
Glucagon-like peptide-1 (GLP-1)-based therapy is a novel treatment for type 2 diabetes. It is executed either by GLP-1 mimetics or by dipeptidyl peptidase-IV inhibitors. In type 2 diabetes, the two strategies reduce hemoglobin A(1c) by 0.6% to 1.1% from baseline levels of 7.7% to 8.5%. They are efficient both in monotherapy and in combination with metformin or thiazolidinediones. Both treatments are well tolerated with low risk of hypoglycemia.
基于胰高血糖素样肽-1（GLP-1）的疗法是2型糖尿病的一种新型治疗方法。它通过GLP-1类似物或二肽基肽酶-IV抑制剂来实施。在2型糖尿病中，这两种策略可使糖化血红蛋白A（1c）从基线水平7.7%至8.5%降低0.6%至1.1%。它们在单药治疗以及与二甲双胍或噻唑烷二酮类药物联合使用时均有效。两种治疗方法耐受性良好，低血糖风险低。
